Evidence map›Paper›PMID 31655566›Full record

ArticleBMC infectious diseases2019

Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool.

Eduard Grebe, Shelley N Facente, Jeremy Bingham, Christopher D Pilcher, Andrew Powrie, Jarryd Gerber, Gareth Priede, Trust Chibawara, Michael P Busch, Gary Murphy and 3 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eduard GrebeVitalant Research Institute, 270 Masonic Avenue, San Francisco, CA, 94118, USA. EGrebe@vitalant.org.ORCID http://orcid.org/0000-0001-7046-7245
Shelley N FacenteVitalant Research Institute, 270 Masonic Avenue, San Francisco, CA, 94118, USA.
Jeremy BinghamDST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, 19 Jonkershoek Avenue, Stellenbosch, 7925, South Africa.
Christopher D PilcherUniversity of California San Francisco, 1001 Potrero Avenue, Room 5H22, San Francisco, CA, 94110, USA.
Andrew PowrieImplicit Design, Block B, North Building Black River Park, 2 Fir St, Observatory, Cape Town, 7925, South Africa.
Jarryd GerberImplicit Design, Block B, North Building Black River Park, 2 Fir St, Observatory, Cape Town, 7925, South Africa.
Gareth PriedeImplicit Design, Block B, North Building Black River Park, 2 Fir St, Observatory, Cape Town, 7925, South Africa.
Trust ChibawaraDST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, 19 Jonkershoek Avenue, Stellenbosch, 7925, South Africa.
Michael P BuschVitalant Research Institute, 270 Masonic Avenue, San Francisco, CA, 94118, USA.
Gary MurphyPublic Health England, 61 Colindale Avenue, London, NW9 5EQ, UK.
Reshma KassanjeeDST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, 19 Jonkershoek Avenue, Stellenbosch, 7925, South Africa.
Alex WelteDST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, 19 Jonkershoek Avenue, Stellenbosch, 7925, South Africa.
Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Bill and Melinda Gates Foundation OPP1115799NIAID NIH HHS P30 AI027763
6 · The paper itself

Abstract

backgroundIt is frequently of epidemiological and/or clinical interest to estimate the date of HIV infection or time-since-infection of individuals. Yet, for over 15 years, the only widely-referenced infection dating algorithm that utilises diagnostic testing data to estimate time-since-infection has been the 'Fiebig staging' system. This defines a number of stages of early HIV infection through various standard combinations of contemporaneous discordant diagnostic results using tests of different sensitivity. To develop a new, more nuanced infection dating algorithm, we generalised the Fiebig approach to accommodate positive and negative diagnostic results generated on the same or different dates, and arbitrary current or future tests - as long as the test sensitivity is known. For this purpose, test sensitivity is the probability of a positive result as a function of time since infection.

methodsThe present work outlines the analytical framework for infection date estimation using subject-level diagnostic testing histories, and data on test sensitivity. We introduce a publicly-available online HIV infection dating tool that implements this estimation method, bringing together 1) curatorship of HIV test performance data, and 2) infection date estimation functionality, to calculate plausible intervals within which infection likely became detectable for each individual. The midpoints of these intervals are interpreted as infection time 'point estimates' and referred to as Estimated Dates of Detectable Infection (EDDIs). The tool is designed for easy bulk processing of information (as may be appropriate for research studies) but can also be used for individual patients (such as in clinical practice).

resultsIn many settings, including most research studies, detailed diagnostic testing data are routinely recorded, and can provide reasonably precise estimates of the timing of HIV infection. We present a simple logic to the interpretation of diagnostic testing histories into infection time estimates, either as a point estimate (EDDI) or an interval (earliest plausible to latest plausible dates of detectable infection), along with a publicly-accessible online tool that supports wide application of this logic.

conclusionsThis tool, available at https://tools.incidence-estimation.org/idt/ , is readily updatable as test technology evolves, given the simple architecture of the system and its nature as an open source project.

Indexed as

InternetAlgorithmsHIV InfectionsHumansSoftwareTimeDiagnostic assaysDiagnosticsHIVInfection datingInfection durationInfection timing

Identifiers

PMID31655566
PMCPMC6815418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.